TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 13.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 502,650 shares of the biopharmaceutical company's stock after acquiring an additional 59,845 shares during the period. Braun Stacey Associates Inc. owned about 0.32% of TG Therapeutics worth $19,819,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of TGTX. Vermillion Wealth Management Inc. bought a new stake in shares of TG Therapeutics in the 4th quarter valued at about $30,000. NBC Securities Inc. increased its holdings in TG Therapeutics by 82,300.0% during the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 823 shares during the period. Golden State Wealth Management LLC raised its stake in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 433 shares in the last quarter. Quadrant Capital Group LLC lifted its holdings in TG Therapeutics by 137.1% during the fourth quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after buying an additional 975 shares during the period. Finally, USA Financial Formulas bought a new stake in TG Therapeutics during the 1st quarter valued at $57,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Insider Buying and Selling at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 10.64% of the company's stock.

TG Therapeutics Stock Up 2.5%

Shares of TGTX traded up $0.91 during trading hours on Friday, hitting $37.20. The company had a trading volume of 681,323 shares, compared to its average volume of 2,915,371. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $5.91 billion, a PE ratio of 153.00 and a beta of 1.91. TG Therapeutics, Inc. has a one year low of $16.65 and a one year high of $46.48. The company's fifty day moving average price is $36.77 and its two-hundred day moving average price is $35.11.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. During the same period in the previous year, the company posted ($0.07) earnings per share. The business's quarterly revenue was up 90.4% compared to the same quarter last year. As a group, equities analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.